Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Pfizer Oncology, New York, NY.
Clin Genitourin Cancer. 2018 Apr;16(2):e327-e333. doi: 10.1016/j.clgc.2017.11.005. Epub 2017 Dec 6.
Cardiac metastases from renal cell carcinoma (RCC) are uncommon and there are limited data regarding the presentation and outcomes of this population. The objective of this study was to evaluate the characteristics and outcomes of patients with RCC with cardiac metastasis without inferior vena cava (IVC) involvement.
We conducted a pooled retrospective analysis of metastatic RCC patients treated in 4 clinical trials. Additionally, we conducted a systematic review of cases reported in the literature from 1973 to 2015. Patients with cardiac metastases from RCC without IVC involvement were included. Patient and disease characteristics were described. Additionally, treatments, response to therapy, and survival outcomes were summarized.
Of 1765 metastatic RCC patients in the clinical trials database, 10 had cardiac metastases without IVC involvement. All patients received treatment with targeted therapy. There was 1 observed partial response (10%) and 6 patients showed stable disease (60%). The median progression-free survival was 6.9 months. The systematic review of reported clinical cases included 39 patients. In these patients, the most common cardiac site of involvement was the right ventricle (51%; n = 20). Patients were treated with medical (28%; n = 11) and/or surgical treatment (49%; n = 19) depending on whether disease was isolated (n = 13) or multifocal (n = 26).
To our knowledge, this is the first series to report on the presentation and outcomes of patients with cardiac metastasis without IVC involvement in RCC. We highlight that although the frequency of patients with cardiac metastases without IVC involvement is low, these patients have a unique clinical presentation and warrant special multidisciplinary management.
肾细胞癌(RCC)的心脏转移并不常见,有关该人群表现和结局的数据有限。本研究的目的是评估无下腔静脉(IVC)受累的 RCC 伴心脏转移患者的特征和结局。
我们对 4 项临床试验中治疗的转移性 RCC 患者进行了汇总回顾性分析。此外,我们还对 1973 年至 2015 年文献中报告的病例进行了系统回顾。纳入无 IVC 受累的 RCC 心脏转移患者。描述患者和疾病特征。此外,还总结了治疗、治疗反应和生存结果。
在临床试验数据库中 1765 例转移性 RCC 患者中,有 10 例存在无 IVC 受累的心脏转移。所有患者均接受靶向治疗。1 例观察到部分缓解(10%),6 例疾病稳定(60%)。无进展生存期中位数为 6.9 个月。报告的临床病例系统回顾包括 39 例患者。在这些患者中,最常见的心脏受累部位是右心室(51%;n=20)。根据疾病是否为孤立性(n=13)或多灶性(n=26),患者分别接受了药物(28%;n=11)和/或手术治疗(49%;n=19)。
据我们所知,这是第一组报告 RCC 无 IVC 受累的心脏转移患者表现和结局的系列研究。我们强调,尽管无 IVC 受累的心脏转移患者频率较低,但这些患者具有独特的临床表现,需要特殊的多学科管理。